CoChat

The many antibiotic resistance and tolerance strategies of Pseudomonas aeruginosa

Sindeldecker, Devin, Stoodley, Paul · 2021 · Biofilm
Cited by 77

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Pseudomonas aeruginosa is a bacterial pathogen associated with a wide range of infections and utilizes several strategies to establish and maintain infection including biofilm production, multidrug resistance, and antibiotic tolerance. Multidrug resistance in P. aeruginosa, as well as in all other bacterial pathogens, is a growing concern. Aminoglycoside resistance, in particular, is a major concern in P. aeruginosa infections and must be better understood in order to maintain effective clinical treatment. In this review, the various antibiotic resistance and tolerance mechanisms of Pseudomonas are explored including: classic mutation driven resistance, adaptive resistance, persister cells, small colony variants, phoenix colonies, and biofilms. It is important to further characterize each of these phenotypes and continue to evaluate antibiotic surviving isolates for novel driving mechanisms, so that we are better prepared to combat the rising number of recurrent and recalcitrant infections.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bioflm.2021.100056

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 101

  1. Malhotra, 2019, Cystic fibrosis and Pseudomonas aeruginosa: the host-microbe interface, Clin Microbiol Rev, 32, 10.1128/CMR.00138-18 · DOI · Paper page
  2. Shah, 2016, Pseudomonas prosthetic joint infections: a review of 102 episodes, J Bone Jt Infect, 1, 25, 10.7150/jbji.15722 · doi:10.7150/jbji.15722
  3. Serra, 2015, Chronic wound infections: the role of Pseudomonas aeruginosa and Staphylococcus aureus, Expert Rev Anti Infect Ther, 13, 605, 10.1586/14787210.2015.1023291 · DOI · Paper page
  4. Ciofu, 2019, Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents-how P. aeruginosa can escape antibiotics, Front Microbiol, 10, 913, 10.3389/fmicb.2019.00913 · DOI · Paper page
  5. Lewis, 2008, Multidrug tolerance of biofilms and persister cells, Curr Top Microbiol Immunol, 322, 107
  6. Zavascki, 2010, Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy, Expert Rev Anti Infect Ther, 8, 71, 10.1586/eri.09.108 · DOI · Paper page
  7. Hall-Stoodley, 2005, Biofilm formation and dispersal and the transmission of human pathogens, Trends Microbiol, 13, 7, 10.1016/j.tim.2004.11.004 · DOI · Paper page
  8. Cross, 1983, Progressive increase in antibiotic resistance of gram-negative bacterial isolates. Walter Reed Hospital, 1976 to 1980: specific analysis of gentamicin, tobramycin, and amikacin resistance, Arch Intern Med, 143, 2075, 10.1001/archinte.1983.00350110053015 · doi:10.1001/archinte.1983.00350110053015
  9. Blahova, 2001, Sudden increase in Pseudomonas aeruginosa nosocomial strains with broad host range transfer of antibiotic resistance, J Chemother, 13, 607, 10.1179/joc.2001.13.6.607 · doi:10.1179/joc.2001.13.6.607
  10. Zignol, 2006, Global incidence of multidrug-resistant tuberculosis, J Infect Dis, 194, 479, 10.1086/505877 · DOI · Paper page
  11. Keen, 2010, Prevalence of multidrug-resistant organisms recovered at a military burn center, Burns, 36, 819, 10.1016/j.burns.2009.10.013 · DOI · Paper page
  12. Tam, 2010, Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa, Antimicrob Agents Chemother, 54, 1160, 10.1128/AAC.01446-09 · DOI
  13. Oliver, 2000, High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection, Science, 288, 1251, 10.1126/science.288.5469.1251 · DOI · Paper page
  14. Gilleland, 1989, Adaptive resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa, J Med Microbiol, 29, 41, 10.1099/00222615-29-1-41 · doi:10.1099/00222615-29-1-41
  15. Poole, 2005, Aminoglycoside resistance in Pseudomonas aeruginosa, Antimicrob Agents Chemother, 49, 479, 10.1128/AAC.49.2.479-487.2005 · DOI · Paper page
  16. Prickett, 2017, Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene, Thorax, 72, 40, 10.1136/thoraxjnl-2015-208027 · DOI
  17. Levin-Reisman, 2017, Antibiotic tolerance facilitates the evolution of resistance, Science, 355, 826, 10.1126/science.aaj2191 · DOI · Paper page
  18. Jalal, 2000, Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients, Antimicrob Agents Chemother, 44, 710, 10.1128/AAC.44.3.710-712.2000 · DOI · Paper page
  19. Bryan, 1976, Gentamicin resistance in clinical-isolates of Pseudomonas aeruginosa associated with diminished gentamicin accumulation and no detectable enzymatic modification, J Antibiot (Tokyo), 29, 743, 10.7164/antibiotics.29.743 · doi:10.7164/antibiotics.29.743
  20. Doi, 1968, Inactivation of kanamycin, neomycin, and streptomycin by enzymes obtained in cells of Pseudomonas aeruginoa, Appl Microbiol, 16, 1276, 10.1128/am.16.9.1276-1281.1968 · doi:10.1128/am.16.9.1276-1281.1968
  21. Brzezinska, 1972, Gentamicin resistance in strains of Pseudomonas aeruginosa mediated by enzymatic N-acetylation of the deoxystreptamine moiety, Biochemistry, 11, 761, 10.1021/bi00755a013 · doi:10.1021/bi00755a013
  22. Kobayashi, 1971, Inactivation of dihydrostreptomycin by Pseudomonas aeruginosa, Jpn J Microbiol, 15, 381, 10.1111/j.1348-0421.1971.tb00596.x · doi:10.1111/j.1348-0421.1971.tb00596.x
  23. Seupt, 2020, Expression of the MexXY aminoglycoside efflux pump and presence of an aminoglycoside-modifying enzyme in clinical Pseudomonas aeruginosa isolates are highly correlated, Antimicrob Agents Chemother, 65, 10.1128/AAC.01166-20 · doi:10.1128/aac.01166-20
  24. Kashfi Mh, 2017, The prevalence of aminoglycoside-modifying enzyme genes among Pseudomonas aeruginosa strains isolated from burn patients, Arch Clin Infect Dis, 12
  25. Rodriguez Esparragon, 2000, Aminoglycoside resistance mechanisms in clinical isolates of Pseudomonas aeruginosa from the Canary Islands, Zentralbl Bakteriol, 289, 817, 10.1016/S0934-8840(00)80008-0 · doi:10.1016/s0934-8840(00)80008-0
  26. Thirumalmuthu, 2019, Mechanisms of fluoroquinolone and aminoglycoside resistance in keratitis-associated Pseudomonas aeruginosa, Microb Drug Resist, 25, 813, 10.1089/mdr.2018.0218 · DOI
  27. Pan, 2017, In vivo host environment alters Pseudomonas aeruginosa susceptibility to aminoglycoside antibiotics, Front Cell Infect Microbiol, 7, 83, 10.3389/fcimb.2017.00083 · doi:10.3389/fcimb.2017.00083
  28. Terzi, 2014, The effects of active efflux pumps on antibiotic resistance in Pseudomonas aeruginosa, World J Microbiol Biotechnol, 30, 2681, 10.1007/s11274-014-1692-2 · DOI
  29. Rampioni, 2017, Effect of efflux pump inhibition on Pseudomonas aeruginosa transcriptome and virulence, Sci Rep, 7, 11392, 10.1038/s41598-017-11892-9 · DOI
  30. Horna, 2018, Interplay between MexAB-OprM and MexEF-OprN in clinical isolates of Pseudomonas aeruginosa, Sci Rep, 8, 16463, 10.1038/s41598-018-34694-z · DOI
  31. Laborda, 2019, Novel inducers of the expression of multidrug efflux pumps that trigger Pseudomonas aeruginosa transient antibiotic resistance, Antimicrob Agents Chemother, 63, 10.1128/AAC.01095-19 · DOI
  32. Halfon, 2019, Structure of Pseudomonas aeruginosa ribosomes from an aminoglycoside-resistant clinical isolate, Proc Natl Acad Sci U S A, 116, 22275, 10.1073/pnas.1909831116 · DOI
  33. Sanz-Garcia, 2019, Analysis of the Pseudomonas aeruginosa aminoglycoside differential resistomes allows defining genes simultaneously involved in intrinsic antibiotic resistance and virulence, Antimicrob Agents Chemother, 63, 10.1128/AAC.00185-19 · doi:10.1128/aac.00185-19
  34. Freschi, 2019, The Pseudomonas aeruginosa pan-genome provides new insights on its population structure, horizontal gene transfer, and pathogenicity, Genome Biol Evol, 11, 109, 10.1093/gbe/evy259 · DOI · Paper page
  35. Hermes, 2013, Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and -resistant Pseudomonas aeruginosa, J Med Microbiol, 62, 1184, 10.1099/jmm.0.059220-0 · DOI
  36. He, 2018, Heteroresistance to carbapenems in invasive Pseudomonas aeruginosa infections, Int J Antimicrob Agents, 51, 413, 10.1016/j.ijantimicag.2017.10.014 · DOI
  37. Xu, 2020, Mechanisms of heteroresistance and resistance to imipenem in Pseudomonas aeruginosa, Infect Drug Resist, 13, 1419, 10.2147/IDR.S249475 · DOI · Paper page
  38. Band, 2019, Heteroresistance: a cause of unexplained antibiotic treatment failure?, PLoS Pathog, 15, 10.1371/journal.ppat.1007726 · DOI · Paper page
  39. Band, 2018, Carbapenem-resistant Klebsiella pneumoniae exhibiting clinically undetected colistin heteroresistance leads to treatment failure in a murine model of infection, mBio, 9, 10.1128/mBio.02448-17 · DOI
  40. Anderson, 2018, Aminoglycoside heteroresistance in acinetobacter baumannii AB5075, mSphere, 3, 10.1128/mSphere.00271-18 · DOI
  41. Nicoloff, 2019, The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification, Nat Microbiol, 4, 504, 10.1038/s41564-018-0342-0 · DOI · Paper page
  42. Band, 2019, Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection, Nat Microbiol, 4, 1627, 10.1038/s41564-019-0480-z · DOI · Paper page
  43. Barclay, 1996, Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis, J Antimicrob Chemother, 37, 1155, 10.1093/jac/37.6.1155 · DOI
  44. Alford, 2021, NtrBC selectively regulates host-pathogen interactions, virulence, and ciprofloxacin susceptibility of Pseudomonas aeruginosa, Front Cell Infect Microbiol, 11, 694789, 10.3389/fcimb.2021.694789 · DOI
  45. Skiada, 2011, Adaptive resistance to cationic compounds in Pseudomonas aeruginosa, Int J Antimicrob Agents, 37, 187, 10.1016/j.ijantimicag.2010.11.019 · DOI
  46. Coleman, 2020, Multidrug adaptive resistance of Pseudomonas aeruginosa swarming cells, Antimicrob Agents Chemother, 64, 10.1128/AAC.01999-19 · doi:10.1128/aac.01999-19
  47. Grassi, 2017, Generation of persister cells of Pseudomonas aeruginosa and Staphylococcus aureus by chemical treatment and evaluation of their susceptibility to membrane-targeting agents, Front Microbiol, 8, 1917, 10.3389/fmicb.2017.01917 · DOI
  48. Renbarger, 2017, Slow and steady wins the race: an examination of bacterial persistence, AIMS Microbiol, 3, 171, 10.3934/microbiol.2017.2.171 · DOI
  49. Hobby, 1942, Observations on the mechanism of action of penicillin, Proc Soc Exp Biol Med, 50, 281, 10.3181/00379727-50-13773 · DOI · Paper page
  50. Bigger, 1944, Treatment of staphylococcal infections with penicillin by intermittent sterilisation, Lancet, 244, 497, 10.1016/S0140-6736(00)74210-3 · DOI · Paper page
  51. Soares, 2019, Understanding ciprofloxacin failure in Pseudomonas aeruginosa biofilm: persister cells survive matrix disruption, Front Microbiol, 10, 2603, 10.3389/fmicb.2019.02603 · DOI
  52. Zhou, 2021, Identification of a toxin-antitoxin system that contributes to persister formation by reducing NAD in Pseudomonas aeruginosa, Microorganisms, 9, 10.3390/microorganisms9040753 · DOI
  53. Andersen, 2017, Diversity, prevalence, and longitudinal occurrence of type II toxin-antitoxin systems of Pseudomonas aeruginosa infecting cystic fibrosis lungs, Front Microbiol, 8, 1180, 10.3389/fmicb.2017.01180 · doi:10.3389/fmicb.2017.01180
  54. Kim, 2010, Toxins Hha and CspD and small RNA regulator Hfq are involved in persister cell formation through MqsR in Escherichia coli, Biochem Biophys Res Commun, 391, 209, 10.1016/j.bbrc.2009.11.033 · DOI · Paper page
  55. Dorr, 2010, Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli, PLoS Biol, 8, 10.1371/journal.pbio.1000317 · DOI · Paper page
  56. Brown, 2009, Three dimensional structure of the MqsR:MqsA complex: a novel TA pair comprised of a toxin homologous to RelE and an antitoxin with unique properties, PLoS Pathog, 5, 10.1371/journal.ppat.1000706 · DOI · Paper page
  57. Gonzalez Barrios, 2006, Autoinducer 2 controls biofilm formation in Escherichia coli through a novel motility quorum-sensing regulator (MqsR, B3022), J Bacteriol, 188, 305, 10.1128/JB.188.1.305-316.2006 · DOI · Paper page
  58. Ren, 2004, Gene expression in Escherichia coli biofilms, Appl Microbiol Biotechnol, 64, 515, 10.1007/s00253-003-1517-y · DOI · Paper page
  59. Hong, 2012, Bacterial persistence increases as environmental fitness decreases, Microb Biotechnol, 5, 509, 10.1111/j.1751-7915.2011.00327.x · DOI · Paper page
  60. Mulcahy, 2010, Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis, J Bacteriol, 192, 6191, 10.1128/JB.01651-09 · DOI · Paper page
  61. Zierdt, 1964, Dissociation in Pseudomonas aeruginosa, J Bacteriol, 87, 1003, 10.1128/jb.87.5.1003-1010.1964 · DOI
  62. Haussler, 1999, Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis, Clin Infect Dis, 29, 621, 10.1086/598644 · DOI · Paper page
  63. Melter Or, 2010, Small colony variants of staphylococcus aureus - review, Folia Microbiol, 55, 10.1007/s12223-010-0089-3 · DOI
  64. Boles, 2004, Self-generated diversity produces "insurance effects" in biofilm communities, Proc Natl Acad Sci U S A, 101, 16630, 10.1073/pnas.0407460101 · DOI · Paper page
  65. Pestrak Mjc, 2018, Pseudomonas aeruginosa rugose small-colony variants evade host clearance, are hyper-inflammatory, and persist in multiple host environments, PLoS Pathog, 14
  66. D'Argenio, 2002, Autolysis and autoaggregation in Pseudomonas aeruginosa colony morphology mutants, J Bacteriol, 184, 6481, 10.1128/JB.184.23.6481-6489.2002 · DOI · Paper page
  67. Ross, 1987, Regulation of cellulose synthesis in Acetobacter xylinum by cyclic diguanylic acid, Nature, 325, 279, 10.1038/325279a0 · DOI · Paper page
  68. Boyd, 2012, Second messenger regulation of biofilm formation: breakthroughs in understanding c-di-GMP effector systems, Annu Rev Cell Dev Biol, 28, 439, 10.1146/annurev-cellbio-101011-155705 · DOI · Paper page
  69. Hickman, 2008, Identification of FleQ from Pseudomonas aeruginosa as a c-di-GMP-responsive transcription factor, Mol Microbiol, 69, 376, 10.1111/j.1365-2958.2008.06281.x · DOI · Paper page
  70. Baraquet, 2012, The FleQ protein from Pseudomonas aeruginosa functions as both a repressor and an activator to control gene expression from the pel operon promoter in response to c-di-GMP, Nucleic Acids Res, 40, 7207, 10.1093/nar/gks384 · DOI · Paper page
  71. Malone, 2010, YfiBNR mediates cyclic di-GMP dependent small colony variant formation and persistence in Pseudomonas aeruginosa, PLoS Pathog, 6, 10.1371/journal.ppat.1000804 · DOI · Paper page
  72. Starkey, 2009, Pseudomonas aeruginosa rugose small-colony variants have adaptations that likely promote persistence in the cystic fibrosis lung, J Bacteriol, 191, 3492, 10.1128/JB.00119-09 · DOI · Paper page
  73. Blanka, 2015, Constitutive production of c-di-GMP is associated with mutations in a variant of Pseudomonas aeruginosa with altered membrane composition, Sci Signal, 8, ra36, 10.1126/scisignal.2005943 · DOI
  74. Kirisits, 2005, Characterization of colony morphology variants isolated from Pseudomonas aeruginosa biofilms, Appl Environ Microbiol, 71, 4809, 10.1128/AEM.71.8.4809-4821.2005 · DOI · Paper page
  75. Hickman, 2005, A chemosensory system that regulates biofilm formation through modulation of cyclic diguanylate levels, Proc Natl Acad Sci U S A, 102, 14422, 10.1073/pnas.0507170102 · DOI · Paper page
  76. Jennings Lks, 2015, Pel is a cationic exopolysaccharide that cross-links extracellular DNA in the Pseudomonas aeruginosa biofilm matrix, Proc Natl Acad Sci U S A, 112
  77. Schiessl, 2019, Phenazine production promotes antibiotic tolerance and metabolic heterogeneity in Pseudomonas aeruginosa biofilms, Nat Commun, 10, 762, 10.1038/s41467-019-08733-w · DOI · Paper page
  78. Glasser Nrk, 2014, Phenazine redox cycling enhances anaerobic survival in Pseudomonas aeruginosa by facilitating generation of ATP and a proton-motive force, Mol Microbiol, 92
  79. McCurtain, 2019, Agmatine accumulation by Pseudomonas aeruginosa clinical isolates confers antibiotic tolerance and dampens host inflammation, J Med Microbiol, 68, 446, 10.1099/jmm.0.000928 · DOI
  80. Sindeldecker, 2020, Novel aminoglycoside-tolerant phoenix colony variants of Pseudomonas aeruginosa, Antimicrob Agents Chemother, 64, 10.1128/AAC.00623-20 · DOI
  81. Satola, 2011, Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method, J Clin Microbiol, 49, 177, 10.1128/JCM.01128-10 · DOI
  82. Tolker-Nielsen, 2015, Biofilm development, Microbiol Spectr, 3, 10.1128/microbiolspec.MB-0001-2014 · DOI · Paper page
  83. Skariyachan, 2018, Recent perspectives on the molecular basis of biofilm formation by Pseudomonas aeruginosa and approaches for treatment and biofilm dispersal, Folia Microbiol, 63, 413, 10.1007/s12223-018-0585-4 · DOI
  84. Maurice, 2018, Pseudomonas aeruginosa biofilms: host response and clinical implications in lung infections, Am J Respir Cell Mol Biol, 58, 428, 10.1165/rcmb.2017-0321TR · DOI · Paper page
  85. Marmont, 2017, PelA and PelB proteins form a modification and secretion complex essential for Pel polysaccharide-dependent biofilm formation in Pseudomonas aeruginosa, J Biol Chem, 292, 19411, 10.1074/jbc.M117.812842 · DOI
  86. Jones, 2017, Psl produced by mucoid Pseudomonas aeruginosa contributes to the establishment of biofilms and immune evasion, mBio, 8, 10.1128/mBio.00864-17 · DOI
  87. Jenal, 2017, Cyclic di-GMP: second messenger extraordinaire, Nat Rev Microbiol, 15, 271, 10.1038/nrmicro.2016.190 · DOI · Paper page
  88. Song, 2018, Cyclic-di-GMP and oprF are involved in the response of Pseudomonas aeruginosa to substrate material stiffness during attachment on polydimethylsiloxane (PDMS), Front Microbiol, 9, 110, 10.3389/fmicb.2018.00110 · DOI
  89. Kahl, 2020, Light-Mediated decreases in cyclic di-GMP levels inhibit structure formation in Pseudomonas aeruginosa biofilms, J Bacteriol, 202, 10.1128/JB.00117-20 · DOI
  90. Mukherjee, 2017, The RhlR quorum-sensing receptor controls Pseudomonas aeruginosa pathogenesis and biofilm development independently of its canonical homoserine lactone autoinducer, PLoS Pathog, 13, 10.1371/journal.ppat.1006504 · DOI · Paper page
  91. Kostylev, 2019, Evolution of the Pseudomonas aeruginosa quorum-sensing hierarchy, Proc Natl Acad Sci U S A, 116, 7027, 10.1073/pnas.1819796116 · DOI · Paper page
  92. Walters, 2003, Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin, Antimicrob Agents Chemother, 47, 317, 10.1128/AAC.47.1.317-323.2003 · DOI · Paper page
  93. Bernier, 2013, Starvation, together with the SOS response, mediates high biofilm-specific tolerance to the fluoroquinolone ofloxacin, PLoS Genet, 9, 10.1371/journal.pgen.1003144 · DOI · Paper page
  94. Nguyen, 2011, Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria, Science, 334, 982, 10.1126/science.1211037 · DOI · Paper page
  95. Nicholle, 2014, Catheter associated urinary tract infections, Antimicrob Resist Infect Contr, 25
  96. Xu Wh, 2015, The effect of infection control nurses on the occurrence of Pseudomonas aeruginosa healthcare-acquired infection and multidrug-resistant strains in critically ill children, PloS One, 10
  97. Mulcahy Lri, 2014, Pseudomonas aeruginosa biofilms in disease, Microb Ecol, 68
  98. Stewart, 2002, Mechanisms of antibiotic resistance in bacterial biofilms, Int J Med Microbiol, 292, 107, 10.1078/1438-4221-00196 · DOI · Paper page
  99. Pachori, 2019, Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review, Genes Dis, 6, 109, 10.1016/j.gendis.2019.04.001 · DOI · Paper page
  100. Pang, 2019, Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies, Biotechnol Adv, 37, 177, 10.1016/j.biotechadv.2018.11.013 · DOI · Paper page
  101. Hoiby, 2017, Diagnosis of biofilm infections in cystic fibrosis patients, APMIS, 125, 339, 10.1111/apm.12689 · DOI

Cited by

See all 77

Metadata

Authors
Sindeldecker, D., & Stoodley, P.
Venue
Biofilm
Publisher
Elsevier BV
Published
2021-12
Volume
3
Pages
100056
ISSN
2590-2075
Cited by
77
References
8
Language
en
Licence
Funders
NIH

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The many antibiotic resistance and tolerance strategies of Pseudomonas aeruginosa. https://app.cochat.ai/papers/10.1016/j.bioflm.2021.100056
The paper
Sindeldecker, D., & Stoodley, P. (2021). The many antibiotic resistance and tolerance strategies of Pseudomonas aeruginosa. Biofilm. https://doi.org/10.1016/j.bioflm.2021.100056

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.